Format

Send to

Choose Destination
Onco Targets Ther. 2012;5:31-46. doi: 10.2147/OTT.S21259. Epub 2012 Mar 5.

Targeted agents for the treatment of metastatic melanoma.

Author information

1
NCIC Clinical Trials Group, Kingston, Ontario, Canada.

Abstract

In the last year, the armamentarium of melanoma therapeutics has radically changed. Recent discoveries in melanoma biology and immunology have led to novel therapeutics targeting known oncogenes and immunotherapeutic antibodies. Phase III clinical trials of these agents have reported measurable and meaningful benefits to patients with metastatic disease. In this article, we review recent findings and discuss their significance in melanoma therapy. As our understanding of melanoma biology grows, this initial therapeutic success may be enhanced through the use of molecular markers to select patients, and new targeted immunotherapies in sequential or combination drug regimens.

KEYWORDS:

antitumor; ipilimumab; metastatic melanoma; vemurafenib

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center